Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980874 · ClinicalTrials.gov registry record · Phase 3
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
A Phase 3 study, sponsored by Clearside Biomedical.
- Terminated
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT02980874: Clinical Trial Phase 3 study, sponsored by Clearside Biomedical.
NCT02980874 is a Phase 3 study that was terminated before completion, run by Clearside Biomedical. The registered enrollment target is 460 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02980874, a Phase 3 study, was terminated before completion, sponsored by Clearside Biomedical.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
Primary Outcome
Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.
Interventions
- DRUG IVT aflibercept
- DRUG suprachoroidal CLS-TA
- DRUG suprachoroidal sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2018-12-10 |
| Phase | Phase 3 |
Why NCT02980874 stopped before completion
NCT02980874 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 3 interventions - of which IVT aflibercept is the first listed.
NCT02980874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02980874 about?
NCT02980874 is a clinical study titled "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO". This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
What is the current status of trial NCT02980874?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2017-01-31. Estimated completion is 2018-12-10.
What interventions are being tested in trial NCT02980874?
The interventions under investigation include: IVT aflibercept (DRUG), suprachoroidal CLS-TA (DRUG), suprachoroidal sham (DRUG).
Who is sponsoring clinical trial NCT02980874?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02980874's enrollment target sits among peer trials
460 823rd of 2000 higher than 1,174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI